Potential solutions for pricing and reimbursement of high-cost combination products
The PRMA Consulting Expert Advisory Group on Complex Pricing recently discussed pricing and reimbursement of high-cost combination products, with a particular focus on oncology therapies.
Drawing on their legal and policy expertise from across the EU, the cross-functional advisors explored the current reimbursement mechanisms for combination products, challenges these present for access for new innovative combinations, the scope for potential solutions, and the current policy direction on this within France, Germany, and the UK. Contact us for a confidential discussion about the findings.
Biosimilars: market access considerations
As the biosimilar market expands, payers are looking to take advantage of potential budget savings. This free eBook summarizes the benefits and challenges for biosimilars, and points for differentiating your product from competitor biosimilars and/or the reference product.
17 anti-cancer drugs have been added to NRDL for national reimbursement in China, with reports of an average 36% lower market price than in surrounding countries >>
First CAR-T assessment issued by CADTH
Read the key findings.
How are digital applications transforming the value and access functions?
Pharmaceutical and biotechnology companies are turning to technology more frequently to solve business issues, and are increasingly using digital technology to optimize market access for their products. We believe that there are three key benefits for market access.
Explore early evidence planning solutions at DIA Europe 2019
Discover how we can help you develop an integrated early evidence strategy that anticipates and navigates the complex market access requirements from pre-clinical development and beyond.
Discover solutions to pricing challenges for high-cost combinations
If you are facing complex pricing challenges, a good place to test your strategies and solutions is the PRMA Expert Advisory Group. This unique global community of experienced, multi-disciplinary experts has proudly gained an international reputation for improving the complex pricing strategies of leading pharmaceutical and biotechnology companies.
Reinvigorate your market access with the PRMA Navigator®
Now is the perfect time to discover how to accelerate time to market, while delivering greater quality and savings. Test-drive the latest version of our cutting-edge digital application.
Drive payer submission readiness for your Phase 2 and 3 products
With a systematic assessment of payer evidence readiness for your product against actual submission template requirements, the PRMA Healthcheck® late module advances your organizational vision and action plan to optimize payer readiness.
Evaluate how digital technology can better enable processes and requirements
Harnessing digital applications to explore value options, gain strategic advantage and provide innovative market access solutions.
PRMA Consulting presents award winning research at ISPOR Europe
We are incredibly proud of our team who have received the award for Best General Poster Research Presentation at ISPOR Europe 2018.
This recognizes the scientific merit of their work, “Impact of European Medicines Agency Clinical Trial Transparency Policies on Health Technology Assessment Decisions in Germany”.
Accelerate the generation of simultaneous HTA submissions
Gain a head start on your HTA submissions with auto-population, delivering up to 80% of a draft submission and maximizing the use of supporting materials.
Join us at the 60th ASH Annual Meeting
Find out how new developments in CAR-T pricing and reimbursement can help you reach your market access goals.
Managed entry agreements lessons from EU5
Gain an insight into different approaches to managed entry agreements at national, regional, and local level by watching this webinar. Understand the practical implications for manufacturers, payers, and healthcare systems, and identify the considerations for the design of effective managed entry agreements
Meet with us at ISPOR Europe
Utilized by Market Access and HEOR professionals from affiliate to global level, the cutting edge PRMA digital applications unlock and optimize value from early product development through to successful HTA submissions. ISPOR Europe provides the perfect opportunity to experience the intuitive functionality of the secure and scalable applications.
Translate advances in oncology and gene therapy into successful market access strategy
Join our international senior team at ESMO 2018 to discuss your specific business challenges, examine global CAR-T insight from complex pricing experts and test-drive the latest, transformative digital applications.
CAR-T therapy: the future begins to take shape
What can HEOR and market access teams learn from CAR-Ts’ early pricing and reimbursement experience and health-system implementation plans? The current status and key issues for pricing and reimbursement of CAR-T therapy in the US, UK, France, and Germany are examined in this presentation. You will gain insight into the practical implications for health technology assessment, patient access, and the development of funding and delivery models within public healthcare systems for these breakthrough therapies.
Leading pharma launches new immunotherapy using insight from the PRMA Tracker®
To support the successful launch of a new immunotherapy for a fast-evolving indication, this noted pharmaceutical company required an in-depth understanding of the latest payer thinking across rapidly advancing global markets. Find out how they approached the challenge.
Maximize the pricing and market access potential of your early pipeline
A top-10 pharmaceutical company sought to make informed decisions for an early pipeline product, with little data available. Find out how they established a consistent approach to comparative assessment of market access risks and opportunities to guide their early decision-making.
Pricing and reimbursement insights for Gene Therapies
A recent meeting of complex pricing experts focused on the challenges and solutions for pricing and reimbursement in the area of innovative cell and gene therapy products. The bespoke group shared knowledge from a range of countries and different roles within healthcare systems, to bring a practical and pragmatic approach to issues related to pricing. We are pleased to share our highlights from this thought-leading meeting.
Yescarta and Kymriah cell therapy: key areas to watch
With NICE’s rejection of Gilead’s Yescarta for treating DLBCL and NHS England’s announcement that a deal has been agreed with Novartis to fund Kymriah for childhood ALL, what are the implications for CAR-T manufacturers and assessment agencies?
Achieving a variable price by indication: free eBook download
For manufacturers seeking to optimize the value of assets in development across multiple indications, there are alternative options to achieve a variable price by indication, other than the classic method of indication-specific rebates. Our free eBook helps you understand the variance in schemes and provides insight for selecting the most appropriate scheme.
Over 40 readiness assessments successfully delivered by the PRMA Healthcheck® late module
PRMA Consulting is celebrating the successful support of over 40 readiness assessments using its digital application, the PRMA Healthcheck® late module. Created to drive payer submission readiness for Phase 2 and 3 products, the application is the result of 5 years’ collaboration with leading pharmaceutical companies to meet their market access challenges.
Indication-based pricing: your free eBook download
Challenges for the commercialization of products that offer different value in different indications may be overcome with indication-based pricing strategies. This free eBook offers you insights into the key concepts and suggests ways to develop a value proposition.
A smarter way to inform product strategy and planning dialogue
With the new version release of the PRMA Healthcheck® late module, you can inform high level conversations regarding product strategy and planning with an easily digestible synopsis of key vulnerabilities and proposed evidence generation projects. This is just one new way that our intuitive application helps you drive payer submission readiness for your Phase 2 and 3 products.
Subscribe now to get the latest updates from PRMA Consulting
Achieve up to 80% auto-population of your first draft HTA submission
A top-5 global pharma company investigated digital solutions from various companies to improve the quality and development timelines of simultaneous HTA submissions. The global team and affiliate countries selected the PRMA Navigator® application to auto-populate a partial submission for each country within 2 weeks.
The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma
Treatment decisions for advanced melanoma are increasingly complex as the landscape quickly evolves. This European expert panel study sought to understand which patient characteristics and disease-related factors inform clinicians' choices of first-line treatment for BRAF-mutated melanoma.
Demonstrating product value through the revised ESMO value framework
This case study outlines the approach taken when a client sought to understand how changes to the ESMO-MCBS would affect the perceived value of their products and how these perceptions aligned with HTA outcomes.
Experience our new digital applications
We warmly invite you to our drinks reception and demonstration of new digital applications at the ISPOR Global Conference in Baltimore, from 6pm on Monday 21 May and Tuesday 22 May on booth 807. This is the ideal opportunity to experience our latest solutions and discuss your specific market access challenges with members of our senior leadership team.
What role does the patient perspective play in determining access to innovative therapies?
Join us at ASCO 2018 to discover more about the differences between the EU and US perspectives on HRQL.
Indication-specific pricing: the obvious solution?
This presentation examines the opportunities and challenges for manufacturers and payers in implementing indication-based pricing strategies. You will gain an understanding of the complexities that multiple indication and combination products present for pricing and reimbursement and obtain actionable insights for developing a value proposition for indication-specific pricing.
Leveraging the value frameworks scoring of a new treatment and comparators
See the approach taken when a client sought to understand how various value frameworks would score their new treatment, in comparison to competitor products, and how this could be leveraged in the value proposition.
Tailored solutions for early planning in market access
Visit booth 29 at DIA Europe and discover how we can help you develop an integrated early evidence strategy that anticipates and navigates complex market access requirements from pre-clinical development and beyond.
Value and Access: striking a balance
Join us in an expert discussion at DIA Europe
Ensuring optimal access at appropriate value is a balancing act. Our senior director, Jan McKendrick, is pleased to be participating in a thought leading discussion at DIA Europe which will address key questions on the topic taking into account multiple perspective. As part of the session, Jan will present international evidence of the impact of reimbursement and licensing discrepancies on patient access before a discussion on harmonisation and the path forward.
Visit booth 29 to discuss this with Jan in more detail.
3 reasons why an expert advisory group can help with your complex pricing challenges
Manufacturers seeking to execute complex pricing schemes rapidly and effectively need to approach payers with well-developed solutions, adapted to a range of country requirements and aligned with the changing landscape. Find out how an expert advisory group can help you with your complex pricing issues
Payer perspectives on cell and gene therapies: 9 key challenges
Assessing payer perspectives on the rapid developments in regenerative medicines and cell therapy, we highlight the key challenges and opportunities for the clinical pipeline.
CAR-Ts therapy and indication-specific pricing in Europe: new insights
A recent meeting of complex pricing experts from across the EU5 countries focused on the variability among countries of payers’ and policy-makers’ attitudes to innovative pricing, and the practical challenges for implementation of complex pricing schemes capable of satisfying a range of country requirements and accommodating the rapidly evolving landscape. We are pleased to share our highlights from this thought-leading meeting.
Insights direct to your inbox
New data protection regulations come into effect this year which mean that you may no longer be among the first to receive our insights for pricing, reimbursement and market access.
Whether you regularly enjoy our thought-leading presentations or just like downloading our case studies and articles from time to time, to continue to receive our updates please let us know now.
Running the half-marathon for Addison's Disease Self-Help Group
A team of colleagues from PRMA Consulting are challenging themselves by running the Fleet half-marathon in March; for one of the group this will be a training run for the Rotterdam marathon a few weeks later!
Through our running, we would like to raise awareness and much needed funds for the Addison's Disease Self-Help Group. We recently became aware of the impact of this disease on a young child and his family; thankfully he survived and is learning to live with his condition.
Launch of the expert advisory group on complex pricing
The PRMA Consulting team are excited to launch the inaugural meeting of our expert advisory group focused on complex pricing. The group will look at recent and emerging US experience with CAR-Ts and evaluate potential pricing models in the EU. We will also discuss the challenges and opportunities to indication-specific pricing in Europe. We will share highlights from this meeting with clients after the holidays.
CAR-Ts: access challenges and opportunities
Following our successful webinar yesterday on ‘Market access considerations for CAR-Ts: insights from ASH’, please find more information about how we can help you with your access challenges and opportunities for CAR-Ts.
Payer perspectives on cell and gene therapies: opportunities and challenges
This new webinar has true cross-functional value for everyone working in market access in the pharmaceutical industry. From non-expert audiences through to subject-matter experts. Professor Stephen Palmer from the University of York will join us to discuss his recent work on the assessment of regenerative medicines and cell therapy, and the UK and EU payer perspective on the potential value of these therapies.
Patient-centricity: shaping value generation for HTA and market access
With patient-centricity becoming a new paradigm for the pharmaceutical industry, this webinar will examine the role of patient engagement in HTA and market access processes, and how this enhances value generation for drug approvals. Focusing on Europe, we will analyze the different models and guidelines in place.
"Please let your staff who supported us know how appreciative we are of their efforts. From the advisory boards to the GVD development to the modeling efforts and numerous projects, the support and partnership was great. The accomplishment in the UK with NICE is absolutely exceptional."
ISPOR Glasgow is nearly upon us! Join us at booth 404 to discuss your market access challenges
Market access update key learnings from ASCO and EHA 2017
In this webinar, we discuss the evolution of value frameworks, the OCM, and incorporating the patient perspective. We also consider the implications for payers of new data on CAR-Ts; key points to think about when planning for market access of a combination; and how payers might handle products approved on the basis of basket trials.
"Just wanted to say great job presenting today. The commercial team increasingly want to be involved in these discussions and your discussion points and delivery were great for the access and broader team. Thanks for making the information practical and insightful. I think the overall response from the team was very positive and the content will ultimately be incredibly helpful for our strategy."
Market access for PD-1 inhibitors: where are we now?
With three products targeting the PD-1 pathway now approved, and other launches expected in 2017, this webinar will take stock of payers’ reactions to the products. Focusing on Europe, we will look at the decisions that have been made to date and discuss these further.